QuidelOrtho Reports Preliminary Q1 Revenue Miss, Citing Weak Respiratory Season and China Headwinds

summarizeSummary

QuidelOrtho announced preliminary Q1 2026 revenue of $615-$620 million, below expectations due to a weak respiratory season, slower China sales, and delayed EMEA orders, alongside projected negative free cash flow for the quarter.

check_boxKey Events

• Preliminary Q1 Revenue Below Expectations

  Reported preliminary unaudited Q1 2026 revenue of $615-$620 million, impacted by a 30% decline in U.S. Influenza-like Illness visits compared to Q1 2025.

• Multiple Headwinds Cited

  Revenue was further affected by slower China distributor sales due to proposed NHSA reimbursement rate reductions and delayed EMEA orders from the Middle East conflict.

• Negative Q1 Free Cash Flow

  The company expects preliminary unaudited free cash flow to be in the range of $(65) to $(70) million for Q1 2026, and negative for the first half of 2026.

• Full-Year Guidance at Low End

  QuidelOrtho believes only the low end of its previously issued full-year 2026 financial guidance remains achievable, indicating a more cautious outlook.

auto_awesomeAnalysis

This filing provides a challenging preliminary outlook for QuidelOrtho's first quarter, with revenue impacted by multiple external factors including a significantly weaker respiratory season, proposed reimbursement cuts in China, and geopolitical disruptions. The projected negative free cash flow for Q1 and the first half of 2026, following a substantial net loss in fiscal year 2025, highlights ongoing financial pressures. While management is taking cost actions and expects positive full-year free cash flow, the confirmation that only the low end of full-year guidance is achievable suggests a difficult path ahead, especially with the stock trading near 52-week lows. Investors should monitor the full earnings report on May 5 for further details on cost actions and the revised outlook.